

FDA approves first immunotherapy drug for breast cancer

March 12 2019



(HealthDay)—The U.S. Food and Drug Administration has given its

blessing to the first immunotherapy regimen for breast cancer.

The combination of immunotherapy (Tecentriq) and chemotherapy (Abraxane) was given accelerated approval for triple-negative [breast cancer](#) that is locally advanced or has metastasized, cannot be surgically removed, and is programmed death-ligand 1-positive, *CNN* reported.

A study published last October in the *New England Journal of Medicine* revealed a median progression-free survival of 7.4 months among patients who received the combination therapy compared with 4.8 months among those who received chemotherapy with a placebo, the FDA said Friday. The study was funded by Genentech Inc., the maker of Tecentriq.

"This is the first time immunotherapy has worked in such a difficult to treat cancer, and is a huge step forward for these [breast cancer patients](#)," study author Peter Schmid, M.D., Ph.D., from the Queen Mary University of London, said in a statement last October, *CNN* reported.

More information: [CNN Article](#)
[Abstract/Full Text](#)
[More Information](#)

Copyright © 2018 [HealthDay](#). All rights reserved.

Citation: FDA approves first immunotherapy drug for breast cancer (2019, March 12) retrieved 26 April 2024 from
<https://medicalxpress.com/news/2019-03-fda-immunotherapy-drug-breast-cancer.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
